3 results
To determine non inferiority of two doses of BI 10773 (10 mg/daily and 25 mg/daily) compared to placebo with respect to first occurrence of any of the adjudicated components of the primary composite Major Adverse Cardiovascular Event endpoint (…
- The studymedication in this clinical study was developed for long-term use in patients with endometriosis associated pelvic pain to release the pain and to avoid to otherwise necessary operation.Primary objective-To assess the dose-response…
The primary objective of this study is• To assess the efficacy of vilaprisan in subjects with uterine fibroids compared to placebo.The secondary objectives of this study are• To assess the efficacy of vilaprisan in subjects with uterine fibroids…